The Food and Drug Administration (FDA) has approved a new drug for the treatment of hypoactive sexual desire disorder in premenopausal women. Bremelanotide (to be marketed as Vyleesi) is used on-demand. Bremelanotide is a peptide [...]
Nearly a third of postmenopausal women experience vaginal changes, including dryness, itching and pain during sex -- symptoms related to the declining levels of estrogen occurring during the transition to menopause. According to a study [...]
Both men and women produce testosterone. The big difference is that the levels are much lower in women, around 15 to 40 ng/dL. In women, testosterone levels begin to decline gradually after the age of 20. In postmenopausal women, testosterone levels are between 0 and 20 ng/dL. Various symptoms have been attributed to falling levels of testosterone in midlife women, including lower sex drive, decreased muscle mass and bone density, decline in cognitive functioning, and depression. Some refer to this constellation of symptoms as “female androgen insufficiency syndrome”; others debate the clinical validity of this diagnosis in women.
Sexual dysfunction is common among postmenopausal women and include a spectrum of problems, including low (or hypoactive) sexual desire, decreased satisfaction, and discomfort. Reports indicate that the prevalence of hypoactive sexual desire ranges from 9% in naturally postmenopausal women up to 26% in younger surgically postmenopausal women. A recent study published in the New England Journal of Medicine evaluates the effectiveness of the testosterone patch for postmenopausal women with low sexual desire.
